The advisory committee on immunization practices' recommendation for use of Moderna COVID-19 vaccine in adults aged ≥18 years and considerations for extended intervals for administration of primary series doses of mRNA COVID-19 vaccines: United States, february 2022

Wallace, Megan; Moulia, Danielle; Blain, Amy E; Ricketts, Erin K; Minhaj, Faisal S; Link-Gelles, Ruth; Curran, Kathryn G; Hadler, Stephen C; !Asif, Amimah; Godfrey, Monica; Hall, Elisha; Fiore, Anthony; Meyer, Sarah; Su, John R; Weintraub, Eric; Oster, Matthew E; Shimabukuro, Tom T; Campos-Outcalt, Doug; Morgan, Rebecca L; Bell, Beth P; Brooks, Oliver; Talbot, H. Keipp; Lee, Grace M; Daley, Matthew F; Oliver, Sara E.
MMWR recomm. rep ; 71(11): 416-421, March 18, 2022. tab
Artículo en Inglés | BIGG | ID: biblio-1397081

Documentos relacionados

  1. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022.
  2. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
  3. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.
  4. Early human B cell signatures of the primary antibody response to mRNA vaccination.
  5. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
  6. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
  7. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
  8. Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers.
  9. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
  10. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.